Gut microbiota transplant capsules for people with alopecia areata
Tests gut microbiota transplant capsules against placebo capsules in adults with alopecia areata.
Key facts
- Who runs it
- University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Registry title
- Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 21 Aug 2025
- Expected to end
- 15 Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Vancomycin, Neomycin and MTT capsules
- Placebo capsules
- Record updated
- 26 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe alopecia areata, an autoimmune hair loss. It tests antibiotics followed by microbiota transplant therapy (MTT) capsules against placebo.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Moderate to severe alopecia areata (SALT score >30%): patch type, totalis or universalis. Hair loss for >=3 months, with no active regrowth at the start.
- Earlier treatment
- People taking a JAK inhibitor must stop it for 1 month before joining and during the study. No intralesional or systemic steroids, anthralin, squaric acid, DPCP, protopic, minoxidil, JAK inhibitors or other hair regrowth drugs within one month of the baseline visit. No earlier MTT or microbiome-based products. No antibiotics in the last 48 hours.
Main reasons for not taking part
- Active gut infection, severe gut movement disorders, bowel blockage, total colectomy, or major gut surgery within 3 months
- Allergy to vancomycin or neomycin, or severe anaphylactic food allergy
- Other scalp skin diseases such as psoriasis or seborrheic dermatitis, or infection or skin cancer in treated areas
- Solid organ transplant within 90 days or treatment for rejection; current intensive cancer treatment
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Patients 18 to 75 years of age with moderate to severe alopecia areata (SALT score >30%)
- Patients with a diagnosis of patch type alopecia areata, totalis, or universalis
- Duration of hair loss >=3 months
- No evidence of active, ongoing regrowth present at baseline
- Females of childbearing potential must have a negative urine or serum pregnancy test at screening and immediately prior to MTT
- Females of childbearing potential must agree to use an effective form of contraception from 14 days prior to study antibiotics through at least 30 days after MTT. Acceptable forms of contraception include oral or intramuscular contraceptives, intrauterine devices, surgical sterilization
- Participants are not enrolled in another clinical study
- If undergoing treatment with a JAK inhibitor, participant is willing to discontinue treatment for 1 month prior to enrollment and throughout the duration of the study
Who cannot take part
- Patients will be eligible to enroll if antibiotic therapy is discontinued for at minimum 48 hours prior to treatment
- Major gastrointestinal surgery (e.g., significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy
- Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy
- Previous MTT or microbiome-based products at any time excluding this study
- Solid organ transplant recipients 90 days post-transplant or on active treatment for rejection
- Patients who have been treated with intralesional steroids, systemic steroids, anthralin, squaric acid, DPCP (diphenylcycloprophenone), protopic, minoxidil, JAK inhibitors or other medication which in the opinion of the investigator may affect hair regrowth, within one month of the baseline visit
- Active gastrointestinal infection at time of enrollment
- Allergy to study antibiotics (vancomycin, neomycin)
- Known or suspected severe gastrointestinal dysmotility disorder, e.g., gastroparesis, pseudo-obstruction, scleroderma with gastrointestinal involvement
- History of total colectomy
- History of severe anaphylactic or anaphylactoid food allergy
- A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study
- History of or existing skin diseases affecting the scalp such as psoriasis or seborrheic dermatitis and patients with evidence of infection or skin cancer in the treated areas
- Patients with active medical conditions or malignancies (except adequately treated basal or squamous cell carcinoma of the skin) which in the opinion of the investigator would increase the risks associated with study participation, including patients with a history of recurrent infections
- Having been administered antibiotics in the last 48 hours
- Requires continued antibiotic use
- Ileus or small bowel obstruction
- Unable or unwilling to comply with protocol requirements
- Expected life expectancy \< 6 months
- Patients in whom the diagnosis of alopecia areata is questionable
- Patients in whom regrowth is present/evident at baseline in the areas to be treated
- Patients unwilling or unable to discontinue treatments known to affect hair regrowth in alopecia areata
- Patients determined by the investigator to have extreme diets
- Pregnant and breastfeeding females
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University of MinnesotaMinneapolis, United StatesContact: Thomas PritchardTaking people
About the trial
What the trial wants to find out
Alopecia Areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the hair follicle and subsequent autoimmune attack. AA affects about 5.3 million people in the United States alone, including males and females across all ethnic groups, with a lifetime risk of 2.1%. Autoimmunity develops against the hair follicle, resulting in non-scarring hair loss that may begin as patches that can coalesce and progress to cover the entire scalp (alopecia totalis) or eventually the entire body (alopecia universalis). In AA, there is no permanent destruction of the hair follicle, and regrowth remains possible. Treatment options for AA include intralesional steroids, topical anthralin, allergic contact dermatitis with diphencyprone (DPCP), dinitrochlorobenzene (DNCB), or squaric acid dibutyl ester (SADBE), and recently janus kinase ( JAK) inhibitors. Despite the recent approval of JAKs for the treatment of extensive alopecia areata, some patients are treatment resistant, suffer relapses, or cannot take an oral immunosuppressive medication.
Read full original descriptionShow less
This study will attempt to elucidate the pre-treatment and post treatment skin and gut microbiome composition to determine whether specific bacterial species may correlate with disease or treatment response. To determine the effects of MTT on immune cell composition and activation systemically and locally in the skin, we will analyze major immune cell populations in peripheral blood samples and collect skin biopsies for histopathology and next generation sequencing analyses. Further, to determine if changes in immune cell populations affect the inflammatory response, we will profile inflammatory cytokines. To identify if changes in the gut microbiota influence the metabolic signature in AA, we will also perform untargeted metabolomics in stool gut microbiome samples and in plasma. Altogether, this comprehensive approach aims to identify the pathogenic immunological mechanisms associated with microbiome composition correlated to pre-treatment disease, post-treatment response, and any non-responders to treatment.
The 2 groups in the trial
- Alopecia Areata study groupTreatment being tested
randomized to receive antibiotics and MTT oral capsule
Treatment: Vancomycin, Neomycin and MTT capsules
- Alopecia Areata control groupPlacebo, for comparison
randomized to receive placebo antibiotics and placebo MTT oral capsule
Treatment: Placebo capsules
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
- Plain-language title
- Gut microbiota transplant capsules for people with alopecia areataGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06747611, who can take part
- Record updated
- 26 June 2026